Prospective evaluation of hepatic steatosis in HIV-infected patients with or without hepatitis C virus co-infection

International Journal of Infectious Diseases

Volumn 16, Issue 5, 2012, Pages

  Li Vecchi, Valentina ^a   Soresi, Maurizio ^a   Giannitrapani, Lydia ^a   Di Carlo, Paola ^a   Mazzola, Giovanni ^a   Colletti, Pietro ^a   Terranova, Antonino ^a   Vizzini, Giovanni ^b   Montalto, Giuseppe ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b MEDITERRANEAN INSTITUTE FOR TRANSPLANTATION AND ADVANCED SPECIALIZED THERAPIES ISMETT   (Italy)

Author keywords

Antiretroviral medication; HIV; HIV HCV co infected; Lipodystrophy; Liver disease; Metabolic syndrome; Non alcoholic fatty liver disease; Steatosis

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; ELASTOGRAPHY; FATTY LIVER; FEMALE; FRAMINGHAM RISK SCORE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LIVER FIBROSIS; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIXED INFECTION; PREVALENCE; PROSPECTIVE STUDY; ULTRASOUND; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; COINFECTION; FATTY LIVER; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84859634051     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2012.01.011     Document Type: Article

References (45)

1. Dam-Larsen S., Franzmann M., Christoffersen P., Jensen L.B., Sørensen T.I., Becker U., et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004, 53:750-755.
2. Ristig M., Drechsler H., Powderly W.G. Hepatic steatosis and HIV infection. AIDS Patient Care STDS 2005, 19:356-365.
3. Bellentani S., Scaglioni F., Marino M., Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010, 28:155-161.
4. van Wijk J.P., Cabezas M.C. Hypertriglyceridemia, metabolic syndrome, and cardiovascular disease in HIV-infected patients: effects of antiretroviral therapy and adipose tissue distribution. Int J Vasc Med 2012, 2012:201027.
5. Piroth L. Liver steatosis in HIV-infected patients. AIDS Rev 2005, 7:197-209.
6. Operskalski E.A., Kovacs A. HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep 2011, 8:12-22.
7. Amorosa V., Synnestvedt M., Gross R., Friedman H., MacGregor R.R., Gudonis D., et al. A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr 2005, 39:557-561.
8. Lemoine M., Barbu V., Girard P.M., Kim M., Bastard J.P., Wendum D., et al. Altered hepatic expression of SREBP-1 and PPAR gamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients. AIDS 2006, 20:387-395.
9. Machado M.V., Oliveira A.G., Cortez-Pinto H. Hepatic steatosis in patients co-infected with human immunodeficiency virus/hepatitis C virus: a meta-analysis of the risk factors. Hepatology 2010, 52:71-78.
10. Ghouri N., Preiss D., Sattar N. Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology 2010, 52:1156-1161.
11. Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010, 363:1341-1350.
12. Guaraldi G., Squillace N., Stentarelli C., Orlando G., D'Amico R., Ligabue G., et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis 2008, 47:250-257.
13. Piccinino F., Sagnelli E., Pasquale G., Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 1986, 2:165-173.
14. Montalto G., Soresi M., Carroccio A., Bascone F., Tripi S., Aragona F., et al. Percutaneous liver biopsy: a safe outpatient procedure?. Digestion 2001, 63:55-60.
15. Maharaj B., Maharaj R.J., Leary W.P., Cooppan R.M., Naran A.D., Pirie D., et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle liver biopsy of the liver. Lancet 1986, 1:523-525.
16. Bellentani S., Saccoccio G., Masutti F., Crocè L.S., Brandi G., Sasso F., et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000, 132:112-117.
17. Joseph A.E., Saverymuttu S.H., al-Sam S., Cook M.G., Maxwell J.D. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol 1991, 43:26-31.
18. Valls C., Iannacconne R., Alba E., Murakami T., Hori M., Passariello R., et al. Fat in the liver: diagnosis and characterization. Eur Radiol 2006, 16:2229-2308.
19. Alberti K.G., Zimmet P., Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005, 366:1059-1061. IDF Epidemiology Task Force Consensus Group.
20. National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
21. Law M.G., Friis-Moller N., El-Sadr W.M., Weber R., Reiss P., D'Arminio Monforte A., et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med 2006, 7:218-230. DAD Study Group.
22. Soares F.M., Costa I.M. HIV-associated facial lipoatrophy: from the advent to current knowledge. An Bras Dermatol 2011, 86:843-864.
23. Sung K.C., Ryan M.C., King B.S., Cho Y.K., Kim B.I., Reaven G.M. Relationship between estimates of adiposity, insulin resistance, and nonalcoholic fatty liver disease in a large group of non diabetic Korean adults. Diabetes Care 2007, 30:2113-2118.
24. Saverymuttu S.H., Joseph A.E., Maxwell J.D. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. BMJ 1986, 292:13-15.
25. Caturelli E., Castellano L., Fusilli S., Palmentieri B., Niro G.A., del Vecchio-Blanco C., et al. Coarse nodular US pattern in hepatic cirrhosis: risk for hepatocellular carcinoma. Radiology 2003, 226:691-697.
26. Soresi M., Giannitrapani L., Florena A.M., La Spada E., Di Gesaro V., Rappa F., et al. Reliability of the bright liver echo-pattern in diagnosing steatosis in patients with cryptogenic and HCV-related hypertransaminasaemia. Clin Radiol 2009, 64:1181-1187.
27. Li Vecchi V., Soresi M., Colomba C., Mazzola G., Colletti P., Mineo M., et al. Transient elastography: a non-invasive tool for assessing liver fibrosis in HIV/HCV patients. World J Gastroenterol 2010, 16:5225-5232.
28. de Lédinghen V., Barreiro P., Foucher J., Labarga P., Castéra L., Vispo M.E., et al. Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy. J Viral Hepat 2008, 15:427-433.
29. Akhtar M.A., Mathieson K., Arey B., Post J., Prevette R., Hillier A., et al. Hepatic histopathology and clinical characteristics associated with antiretroviral therapy in HIV patients without viral hepatitis. Eur J Gastroenterol Hepatol 2008, 20:1194-1204.
30. Ingiliz P., Valantin M.A., Duvivier C., Medja F., Dominguez S., Charlotte F., et al. Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 monoinfected patients on antiretroviral therapy. Hepatology 2009, 49:436-442.
31. Crum-Cianflone N., Dilay A., Collins G., Asher D., Campin R., Medina S., et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr 2009, 50:464-473.
32. Lesi O.A., Soyebi K.S., Eboh C.N. Fatty liver and hyperlipidemia in a cohort of HIV-positive Africans on highly active antiretroviral therapy. J Natl Med Assoc 2009, 101:151-155.
33. Ryan P., Blanco F., García-Gascó P., García-Merchán J., Vispo E., Barreiro P., et al. Predictors of severe hepatic steatosis using abdominal ultrasound in HIV-infected patients. HIV Med 2009, 10:53-59.
34. Machado M., Cortez-Pinto H. Non-alcoholic steatohepatitis and metabolic syndrome. Curr Opin Clin Nutr Metab Care 2006, 9:637-642.
35. McGovern B.H., Ditelberg J.S., Taylor L.E., Gandhi R.T., Christopoulos K.A., Chapman S., et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis 2006, 43:365-372.
36. Monto A., Dove L.M., Bostrom A., Kakar S., Tien P.C., Wright T.L. Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection. Hepatology 2005, 42:310-316.
37. Woreta T.A., Sutcliffe C.G., Mehta S.H., Brown T.T., Higgins Y., Thomas D.L., et al. Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology 2010, 140:809-817.
38. Sutinen J., Hakkinen A.M., Westerbacka J., Seppälä-Lindroos A., Vehkavaara S., Halavaara J., et al. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 2002, 16:2183-2193.
39. Grinspoon S., Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005, 352:48-62.
40. Hamaguchi M., Kojima T., Itoh Y., Harano Y., Fujii K., Nakajima T., et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol 2007, 102:2708-2715.
41. Sánchez-Conde M., Montes-Ramírez M.L., Miralles P., Alvarez J.M., Bellón J.M., Ramírez M., et al. Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers. J Viral Hepat 2010, 17:280-286.
42. Lupsor M., Badea R., Stefanescu H., Grigorescu M., Serban A., Radu C., et al. Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis. J Gastrointestin Liver Dis 2010, 19:53-60.
43. Sánchez-Conde M., Montes Ramírez M.L., Bellón Cano J.M., Caminoa A., Rodríguez F.A., Garcia J.G., et al. Impact of liver steatosis on the correlation between liver stiffness and fibrosis measured by transient elastography in patients coinfected with human immunodeficiency virus and hepatitis C virus. J Viral Hepat 2011, 18:278-283.
44. Treeprasertsuk S., Francisco Lopez-Jimenez F., Lindor K.D. Nonalcoholic fatty liver disease and the coronary artery disease. Dig Dis Sci 2011, 56:35-45.
45. Calza L., Masetti G., Piergentili B., Trapani F., Cascavilla A., Manfredi R., et al. Prevalence of diabetes mellitus, hyperinsulinaemia and metabolic syndrome among 755 adult patients with HIV-1 infection. Int J STD AIDS 2011, 22:43-45.